N/A N=40 Self-Management App for Patients With Left-Ventricular Assist Devices
Heart Failure
Primary: Health-related Quality of Life — 49.8; 53.8; 72.7; 57.6 score on a scale — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=22 Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas
Neurofibromatosis Type 2 · Progressive Vestibular Schwannomas
Primary: Improvement in Hearing — 9 Participants
Phase 3 N=862 Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris
Acne Vulgaris
Primary: Percent Change in the Inflammatory (Papules and Pustules) Lesion Counts — -63.81; -67.56; -53.78 percentage of change — p=0.0001
Phase 2 N=154 A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria
Chronic Kidney Disease · Type 2 Diabetes Mellitus
Primary: Changes in Urine Albumin to Creatinine Ratio (UACR) — -64.6; 104.8 mg/g — p=0.279
Phase 2 N=149 Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
Anal Cancer · Nonneoplastic Condition · Penile Cancer
Primary: Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 6 DNA — 0.0; 11.1 Events per 100 person years — p=0.112
N/A N=50 Syncope Decision Aid for Emergency Care
Syncope
Primary: Number of Participants at End of Study — 20; 24 Participants
Phase 2 N=142 Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
Alopecia Areata
Primary: Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 — 32.54; 50.59; 1.41 units on a scale — p=<.0001
Phase 2 N=12 Modafinil for the Treatment of Alcohol Use Disorders
Alcohol Use Disorder
Primary: Time to Relapse — 16; 43 days
Phase 2 N=40 Preventing Stem Cell Transplant Complications With a Blood Separator Machine
MDS (Myelodysplastic Syndrome) · Myeloproliferative Disorder · Lymphoma, Non-Hodgkin
Primary: Overall Survival — 36 Participants
Phase 1 N=6 Experimental Falciparum Transmission to Anopheles
Malaria
Primary: Successful Infection of Vector Mosquitoes Following Both Direct and Indirect Feeding on the Blood of Infected Participants
Phase 2 N=23 Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation
Melanoma
Primary: Percentage of Participants With Relapse Free Survival — 28.6 percentage of participants
Phase 3 N=608 A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
Multiple Sclerosis, Relapsing-Remitting
Primary: Percentage of Participants Without Any Protocol-Defined Events During 96-Week Period — 48.1 Percentage of Participants
Phase 4 N=43 Chloroprocaine Spinal Anesthesia for Cervical Cerclage (CP Spinal)
Adverse Reaction to Spinal Anesthetic · Maternal Care for Cervical Incompetence
Primary: Time to Resolution of Motor Block — 109; 112 minutes
Phase 3 N=129 SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study
Eosinophilic Gastrointestinal Disorders (EGIDs) · Eosinophilic Esophagitis (EoE)
Primary: Percent of Participants in Histologic Remission (<15 Eos/Hpf) — 34.3; 40.3 percentage of participants — p=0.58
Phase 2 N=237 A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
Hormone Receptor Positive Breast Cancer · HER-2 Positive Breast Cancer
Primary: Progression Free Survival (PFS) — 8.3; 5.7; 5.7 Months — p=0.0506